Anti-NLRC5 Antibody, clone 3H8

Poids réel (observé) : env. 205 kDa. 204,6 kDa (isoforme 1) et 201,3 kDa (isoforme 4) (poids calculés). Une ou plusieurs bandes non caractérisées peuvent apparaître avec certains lysats.

The protein named NLRC5, or also known as Nucleotide-binding oligomerization domain protein 27, Caterpiller protein 16.1 (CLR16.1), or Nucleotide-binding oligomerization domain protein 4 and encoded by the gene NLRC5/NOD27/NOD4, plays a role in the homeostatic control of innate immunity and anti-viral defense mechanisms. NLRC5 also likely regulates the NF kappa B and type 1 interferon signaling response pathways induced upon infection. NLRC5 interacts with CHUK and IKBKB and prevents CHUK and IKBKB phosphorylation thus inhibiting their kinase activity. NLRC5 interacts with DDX58 and IFIH1 proteins and blocks the interaction of MAVS to DDX58 proteins. NLRC5 is localized to the cytoplasm. NLRC5 is expressed in spleen, thymus, lung, brain, tonsil, heart and prostate at moderate levels, but NLRC5 expression is dramatically induced by interferons during pathological infections. Traditional immune responses studies have demonstrated that NLRC5 is a specific and master regulator of major histocompatibility complex (MHC) class I genes as well as related genes involved in MHC class I antigen presentation. The expression of MHC class I genes is regulated by NLRC5 in coordination with the RFX components through an enhanceosome-dependent manner, and the involvement of NLRC5 in MHC class I mediated CD8+ T cell activation, proliferation and cytotoxicity has proved to be critical for host defense against intracellular bacterial infections.

BSA-conjugated linear peptide corresponding to the C-terminal sequence of human NLRC5.

&

Analyse par cytométrie en flux : µ

A representative lot detected poly(I:C) (Cat. No. 528906) treatment-induced upregulation of endogenous NLRC5 in HeLa cells by IP-Western blotting analysis of both cytosolic and nuclear fractions. A strong NLRC5 nuclear accumulation was seen upon nuclear export inhibition by LepB (Cat. No. 431050) treatment, whereas NLRC5 was mainly cytoplasmic in untreated cells (Neerincx, A., et al. (2012).

A representative lot detected NLRC5 in THP-1 cell lysate as well as exogenously expressed FLAG-tagged NLRC5 in lysate from transfected HEK293T cells. Target band detection was greatly diminished using lysates from NLRC5 siRNA-transfected THP-1 cells. (Neerincx, A., et al. (2010). J. Biol. Chem. 285(34):26223-26232).

Domaine de recherche
Inflammation et immunologie

Sous-domaine de recherche
Immunoglobulines et immunologie

Target specificity of clone 3H8 was confirmed by Western blotting using lysates from cells overexpressing exogenously transfected NLRC5 as well as cells knocked down of endogenous NLRC5 by shRNA transfection (Neerincx, A., et al. (2010). J. Biol. Chem. 285(34):26223-26232). Clone 3H8 epitope is present in human NLRC5 spliced isoforms 1 and 4, but absent from isoforms 2, 3, 5, and 6 reported by UniProt (Q86WI3).

IgG1κ monoclonale de rat purifiée, dans un tampon à base de Tris-glycine 0,1 M (pH 7,4) et de NaCl 150 mM contenant 0,05 % d'azoture de sodium.

Produit purifié sur protéine G

Stable entre 2 et 8 °C pendant 1 an à compter de la date de réception.

Produit évalué par western blotting sur des lysats de cellules de Raji.

Analyse par western blotting : µµ

Concentration : pour connaître la concentration spécifique du lot, voir le certificat d'analyse.

Sauf indication contraire dans notre catalogue ou toute autre documentation associée au(x) produit(s), nos produits sont uniquement destinés à la recherche et ne sauraient être utilisés à d'autres fins, ce qui inclut, sans s'y limiter, les utilisations commerciales non autorisées, les utilisations diagnostiques in vitro, les utilisations thérapeutiques ex vivo ou in vivo, ou tout type de consommation ou d'application chez l'être humain ou chez l'animal.